open access

Vol 65, No 5 (2015)
Invited editorial
Published online: 2015-11-18
Get Citation

Role of progesterone receptor in luminal breast cancers

Wojciech Kuncman, Marcin Braun, Radzisław Kordek
DOI: 10.5603/NJO.2015.0075
·
Nowotwory. Journal of Oncology 2015;65(5):383-388.

open access

Vol 65, No 5 (2015)
Invited editorial
Published online: 2015-11-18

Abstract

In clinical practice luminal B breast tumours are characterised by having estrogen receptor, the absence of HER2, and a lack or low levels of progesterone receptor, optionally with a high index of Ki67. However, the actual molecular classification of luminal cancers is based on differences in the expression of the whole panel of genes, not only those related to the above mentioned receptors. Luminal B cancers, are in fact, estrogen receptor positive tumours, but with worse outcome. Recently, it is frequently suggested that the luminal B tumours are a group in which the func­tion of the estrogen receptor is not critical and other pathways are over-activated, which are related with growth factors: for example epithelial (EGF), insulin-like (IGF ) or fibroblast (FGF). Surprisingly there are also many interactions between various growth factors with estrogen receptor. This paper presents the heterogeneity of breast cancer. It is also a starting point for further research.

Abstract

In clinical practice luminal B breast tumours are characterised by having estrogen receptor, the absence of HER2, and a lack or low levels of progesterone receptor, optionally with a high index of Ki67. However, the actual molecular classification of luminal cancers is based on differences in the expression of the whole panel of genes, not only those related to the above mentioned receptors. Luminal B cancers, are in fact, estrogen receptor positive tumours, but with worse outcome. Recently, it is frequently suggested that the luminal B tumours are a group in which the func­tion of the estrogen receptor is not critical and other pathways are over-activated, which are related with growth factors: for example epithelial (EGF), insulin-like (IGF ) or fibroblast (FGF). Surprisingly there are also many interactions between various growth factors with estrogen receptor. This paper presents the heterogeneity of breast cancer. It is also a starting point for further research.

Get Citation
About this article
Title

Role of progesterone receptor in luminal breast cancers

Journal

Nowotwory. Journal of Oncology

Issue

Vol 65, No 5 (2015)

Article type

Invited editorial

Pages

383-388

Published online

2015-11-18

Page views

786

Article views/downloads

13495

DOI

10.5603/NJO.2015.0075

Bibliographic record

Nowotwory. Journal of Oncology 2015;65(5):383-388.

Authors

Wojciech Kuncman
Marcin Braun
Radzisław Kordek

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl